Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fluidigm Announces Conference Call and Webcast of Fourth Quarter and Full Year 2018 Financial Results
SOUTH SAN FRANCISCO, Calif. , Jan. 14, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technologies, announced today that it will report fourth quarter and full year 2018 financial results on Thursday, February 7, 2019 , after the close of
View HTML
Toggle Summary Caprion Biosciences Offers Mass Cytometry CRO Services to Advance Biomarker Discovery and Immune Monitoring
Mass cytometry services for pharmaceutical and biotechnology companies to accelerate development of new health insights SOUTH SAN FRANCISCO, Calif. and MONTREAL , Jan. 08, 2019 (GLOBE NEWSWIRE) -- Caprion Biosciences, a world-leading specialty contract research organization (CRO) laboratory
View HTML
Toggle Summary Fluidigm Announces Closing of Public Offering of 9,372,500 Shares of Common Stock Including Full Exercise of Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif. , Dec. 14, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, today announced the closing of its previously announced underwritten public offering of 9,372,500 shares of its common stock.
View HTML
Toggle Summary Fluidigm Announces Pricing of Public Offering of 8,150,000 Shares of Common Stock
SOUTH SAN FRANCISCO, Calif. , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, today announced the pricing of an underwritten public offering of 8,150,000 shares of its common stock at a price to the public of $6.75
View HTML
Toggle Summary Fluidigm Announces Commencement of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten
View HTML
Toggle Summary Fluidigm to Participate in the 30th Annual Piper Jaffray Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, announced today that the company’s management team will participate in the 30 th Annual Piper Jaffray Healthcare Conference in New York :
View HTML
Toggle Summary Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , Nov. 09, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that the Compensation Committee of its Board of Directors, which is comprised entirely of independent directors, granted equity awards effective as of November 6, 2018 , under
View HTML
Toggle Summary Fluidigm Showcases Immuno-Oncology Innovations for Translational and Clinical Research at SITC 2018
A comprehensive suite of innovative immuno-oncology applications to improve the future of cancer care SOUTH SAN FRANCISCO, Calif. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technology, is showcasing its latest innovations for
View HTML
Toggle Summary Fluidigm Recognized as a Company to Watch in 2019
Immuno-oncology innovator receives life science people’s choice award SOUTH SAN FRANCISCO, Calif. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- BioInformatics Inc. , the leading research and advisory firm serving the life science tool market, today announced Fluidigm as the Company to Watch in 2019 at the
View HTML
Toggle Summary Fluidigm Announces Third Quarter 2018 Financial Results
Total revenue increases 17 percent to $29.0 million Mass cytometry revenue growth of 50 percent Instrument revenue growth of 32 percent SOUTH SAN FRANCISCO, Calif. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced financial results for the third quarter ended
View HTML